Improved And Rebalanced Helper And RepCap Plasmids To Ramp Up Your AAV Productivity

Strong growth in the recombinant AAV (rAAV)-based gene therapy sector is creating a need for dramatically increased production of rAAV vectors. Physically increasing manufacturing capacity is neither sufficient or cost-effective. In this webinar, Dr Lisa Prendergast will review how Lonza has further improved its suspension HEK293 based platform with engineered plasmids. These afford significantly higher titers and productivity levels compared to standard systems. These technologies have now been incorporated in XciteTM AAV, our suspension rAAV manufacturing platform and it is now available to take to your labs. Learn how AAV productivity can be optimized using platform technologies.